Identification of 15 novel risk loci for coronary artery disease and genetic risk of recurrent events, atrial fibrillation and heart failure

Niek Verweij1, Ruben N. Eppinga1, Yanick Hagemeijer1,2 & Pim van der Harst1,2,3

Coronary artery disease (CAD) is the major cause of morbidity and mortality in the world. Identification of novel genetic determinants may provide new opportunities for developing innovative strategies to predict, prevent and treat CAD. Therefore, we meta-analyzed independent genetic variants passing \( P < 10^{-5} \) in CARDioGRAMplusC4D with novel data made available by UK Biobank. Of the 161 genetic variants studied, 71 reached genome wide significance (\( p < 5 \times 10^{-8} \)) including 15 novel loci. These novel loci include multiple genes that are involved in angiogenesis (\( TGFB1, ITGB5, CDH13 \) and \( RHOA \)) and 2 independent variants in the \( TGFB1 \) locus. We also identified \( SGEF \) as a candidate gene in one of the novel CAD loci. \( SGEF \) was previously suggested as a therapeutic target based on mouse studies. The genetic risk score of CAD predicted recurrent CAD events and cardiovascular mortality. We also identified significant genetic correlations between CAD and other cardiovascular conditions, including heart failure and atrial fibrillation. In conclusion, we substantially increased the number of loci convincingly associated with CAD and provide additional biological and clinical insights.

Coronary artery disease (CAD) is a major burden of morbidity and mortality to Western society1. CAD is driven by a complex interplay of multiple genetic and environmental factors that jointly give rise to a plethora of molecular interactions resulting in a complex and heterogeneous phenotype. The hallmark of CAD is the development and progression of atheromatous narrowing of the coronary artery with an increasing risk of plaque rupture, resulting in acute coronary occlusion. Current preventive therapy for individuals at risk is directed towards the management of their lipid profile, blood pressure and promoting a healthy lifestyle. Genome-wide association studies (GWAS) have rapidly expanded our knowledge and provided novel leads to gain insights into human biology, optimize risk management and devise new therapeutic strategies2. To date, 57 loci have been reported by genome-wide association studies for CAD, mainly driven by efforts of the CARDioGRAM- and C4D-consortia3. These genetic associations have identified genes that are among the targets of known and possible novel CAD therapies such as \( LDLR \) and \( HMGCR \) (HMG-coA reductase inhibitors, statins), \( PCSK9 \) (PCSK9 inhibitors) and \( IL6R \) (Tocilizumab)4, 5. Genetic association analyses have also identified therapeutic targets for many other conditions as well (reviewed by Plenge et al.4).

To further build upon our biological knowledge of CAD, to facilitate the identification of additional therapeutic targets, and to gain novel insights in the causal relationships between other cardiovascular phenotypes, continuous efforts directed at expanding the number of genetic regions associated with CAD are of paramount importance. Therefore, we set 3 goals. 1) Validate and identify novel loci by follow-up of the top-signals identified in the previous GWAS by the CARDioGRAM-C4D consortium 2) determine biological pathways and candidate genes underlying the genome wide associated loci and 3) evaluate the association of the variants with common risk factors of CAD and common cardiovascular disorders to gain more insight into potential mediators of CAD per locus and trait.

Coronary artery disease (CAD) is the major cause of morbidity and mortality in the world. Identification of novel genetic determinants may provide new opportunities for developing innovative strategies to predict, prevent and treat CAD. Therefore, we meta-analyzed independent genetic variants passing \( P < 10^{-5} \) in CARDioGRAMplusC4D with novel data made available by UK Biobank. Of the 161 genetic variants studied, 71 reached genome wide significance (\( p < 5 \times 10^{-8} \)) including 15 novel loci. These novel loci include multiple genes that are involved in angiogenesis (\( TGFB1, ITGB5, CDH13 \) and \( RHOA \)) and 2 independent variants in the \( TGFB1 \) locus. We also identified \( SGEF \) as a candidate gene in one of the novel CAD loci. \( SGEF \) was previously suggested as a therapeutic target based on mouse studies. The genetic risk score of CAD predicted recurrent CAD events and cardiovascular mortality. We also identified significant genetic correlations between CAD and other cardiovascular conditions, including heart failure and atrial fibrillation. In conclusion, we substantially increased the number of loci convincingly associated with CAD and provide additional biological and clinical insights.

1University of Groningen, University Medical Center Groningen, Department of Cardiology, 9700, RB, Groningen, The Netherlands. 2University of Groningen, University Medical Center Groningen, Department of Genetics, 9700, RB, Groningen, The Netherlands. 3Durrer Center for Cardiogenetic Research, Netherlands Heart Institute, 3511GC, Utrecht, The Netherlands. Correspondence and requests for materials should be addressed to P.v.d.H. (email: p.van.der.harst@umcg.nl)
Results
First, we identified UK Biobank individuals with and without CAD. The prevalence and incidence of CAD conditions and events was captured by data collected at the Assessment Centre in-patient Health Episode Statistics (HES) and at any of the visits. A detailed definition of CAD can be found in the methods section and supplementary material.

Naturally, non-CAD individuals defined the control population but to improve statistical power we excluded individuals from the control population if their mother, father or sibling was reported to suffer from ‘heart disease’. We validated this approach by constructing a genetic risk score based on the 57 previously reported loci weighted with the effect estimates of the CARDIoGRAMplusC4D 1000 Genomes analysis assuming an additive model. The genetic risk score was associated with a family history of heart disease ($n_{cases} = 71,263$, $n_{controls} = 76,535$, $p = 3 \times 10^{-128}$) in UK Biobank. Moreover, increased significance was observed for the association between the genetic risk score and CAD after excluding participants in the control group based on a family history ($p = 5 \times 10^{-183}$), compared to including these individuals ($p = 2 \times 10^{-147}$). Indicating that incorporating family history into the phenotype definition increases statistical power to detect associations between genetic variants and CAD.

This approach identified a total of 10,898 CAD cases and 76,535 non-CAD controls in UK Biobank that were imputed to the 1000 Genomes and UK10K reference panel. The average age for CAD identified participants was 61.5 years and 55.8 for the controls. Detailed baseline characteristics are presented in Supplementary Table 1. To account for potential population stratification and genotyping differences, all associations in this manuscript were adjusted for the first 15 principle components, genotyping chip, gender and age.

Replication and identification of novel CAD loci. To date, 57 loci have been associated with CAD. We performed logistic regressions between CAD status and these 57 previously reported CAD loci: 42 loci replicated at FDR < 0.05 in UK Biobank (Supplementary Table 2). A schematic overview of the 2-stage design to identify new CAD loci is presented in Fig. 1. We first clumped genetic variants on LD ($r^2 < 0.05$, 1000 Genomes phase 1 v3 European panel) that reached a $P$ value of $< 1 \times 10^{-5}$ in the latest CARDIoGRAMplusC4D GWAS. This resulted in 161 independent sets of variants sharing 120 independent loci (defined as 1 MB at either side of the sentinel genetic variant; Supplementary Table 3). Seventy-one genetic variants in 52 loci were significantly associated (FDR < 0.05) with CAD in UK Biobank, were directionally concordant with CARDIoGRAMplusC4D, and were genome wide significant ($p < 5 \times 10^{-8}$) in the joint (meta-) analysis of UK Biobank and CARDIoGRAMplusC4D. Of these 52 loci, 37 were previously reported as genome-wide significant loci for CAD leaving 15 novel genome wide significant loci (Table 1, Supplementary Figure 1). All of the 15 novel loci were common. The minor allele frequency was above 7.6% with relatively weak effect sizes.

Candidate genes and pathway analyses. We prioritized 104 candidate genes in the 52 loci: 70 genes were prioritized based on proximity (the nearest gene and any additional gene within 10 kb), 13 genes by coding genetic variants in linkage disequilibrium ($r^2 > 0.8$) with the sentinel genetic variant (Supplementary Table 4) and 51 genes based on expression quantitative trait loci (eQTL) analyses (Supplementary Table 5). Finally, 25 candidate genes were prioritized based on DEPICT analyses (Supplementary Table 6). The DEPICT framework also identified 458 reconstituted gene sets that can be captured in 48 meta-genesets (Fig. 2), the most significant gene set was ‘abnormal vitelline vasculature morphology’ (Supplementary Table 7); ‘Arteries’ was the only significantly prioritized tissue-type (FDR < 0.01, Supplementary Table 8). Network analysis identified ‘regulation of cell motility’ as the meta-geneset that was most central among all meta-genesets, together with ‘negative regulation of cell motility’ and ‘blood vessel development’, suggesting these pathways play an important role in CAD. More specific...
The genetic risk score significantly predicted these outcomes in cox’s proportional hazards models (Table 3). In mortality, death from coronary artery disease, death from myocardial infarction, and death from heart failure. Attack), atrial fibrillation and diabetes; whereas cardiomyopathy, diastolic blood pressure and arterial stiffness of heart failure, hypertension, smoking, device implantation, cerebral infarction (including transient ischemic mean arterial pressure, pulse pressure and heart rate. The genetic risk score was also associated with the presence genetic variants was associated with multiple other cardiovascular phenotypes and risk factors in UK Biobank (n additon, the genetic risk score predicted recurrent CAD events (n are presented in Supplementary Table 11. Of the 71 genetic variants, 63 were nominally associated (p is highly associated with total cholesterol and LDL (p with one or more phenotypes. These lookups confirmed our findings of the GW AS-catalog query; rs2244608 (OASL) GW AS-catalog for previously reported genome wide associations: for the novel loci, genetic variants in linkage processes identified by DEPICT included hemostasis, anemia and increased leucocyte cell number. The function of each novel candidate gene has been summarized in the Supplementary Note.

**Mediating effects of CAD variants.** CAD is a complex multifactorial disease, sharing biology with other atherosclerotic manifestations and vascular diseases. Therefore, we examined the association between genetic risk for CAD and several common cardiovascular phenotypes. We constructed a weighted genetic risk score by summing the number of CAD increasing risk alleles after multiplying the alleles with the corresponding risk for CAD and several common cardiovascular phenotypes. We constructed a weighted genetic risk score (based on the CARDIoGRAMplusC4D GW AS3). The genetic risk score that was based on the 71 independent genetic variants was associated with multiple other cardiovascular phenotypes and risk factors in UK Biobank (Table 2). At baseline, the genetic risk score was significantly associated with BMI, height, systolic blood pressure, mean arterial pressure, pulse pressure and heart rate. The genetic risk score was also associated with the presence of heart failure, hypertension, smoking, device implantation, cerebral infarction (including transient ischemic attack), atrial fibrillation and diabetes; whereas cardiomyopathy and diabetes; whereas cardiomyopathy and diabetes; whereas cardiomyopathy and diabetes; whereas cardiomyopathy and diabetes; whereas cardiomyopathy and diabetes; whereas cardiomyopathy and diabetes; whereas cardiomyopathy and diabetes; whereas cardiomyopathy and diabetes; whereas cardiomyopathy and diabetes; whereas cardiomyopathy and diabetes; whereas cardiomyopathy and diabetes; whereas cardiomyopathy and diabetes; whereas cardiomyopathy and diabetes; whereas cardiomyopathy and diabetes; whereas cardiomyopathy and diabetes; whereas cardiomyopathy and diabetes; whereas cardiomyopathy and diabetes; whereas cardiomyopathy and diabetes; whereas cardiomyopathy and diabetes; whereas cardiomyopathy and diabetes; whereas cardiomyopathy and diabetes; whereas cardiomyopathy and diabetes; whereas cardiomyopathy and diabetes; whereas cardiomyopathy and diabetes; whereas cardiomyopathy and diabetes; whereas cardiomyopathy and diabetes; whereas cardiomyopathy and diabetes; whereas cardiomyopathy and diabetes; whereas cardiomyopathy and diabetes; whereas cardiomyopathy and diabetes; whereas cardiomyopathy and diabetes; whereas cardiomyopathy and diabetes; whereas cardiomyopathy and diabetes; whereas cardiomyopathy and diabetes; whereas cardiomyopathy and diabetes; whereas cardiomyopathy and diabetes; whereas cardiomyopathy and diabetes; whereas cardiomyopathy and diabetes; whereas cardiomyopathy and diabetes; whereas cardiomyopathy and diabetes; whereas cardiomyopathy and diabetes; whereas cardiomyopathy and diabetes; whereas cardiomyopathy and diabetes; whereas cardiomyopathy and diabetes; whereas cardiomyopathy and diabetes; whereas cardiomyopathy and diabetes; whereas cardiomyopathy and diabetes; whereas cardiomyopathy and diabetes; whereas cardiomyopathy and diabetes; whereas cardiomyopathy and diabetes; whereas cardiomyopathy and diabetes; whereas cardiomyopathy and diabetes; whereas cardiomyopathy and diabetes; whereas cardiomyopathy and diabetes; whereas cardiomyopathy and diabetes; whereas cardiomyopathy and diabetes; whereas cardiomyopathy and diabetes; whereas cardiomyopathy and diabetes; whereas cardiomyopathy and diabetes; whereas cardiomyopathy and diabetes; whereas cardiomyopathy and diabetes; whereas cardiomyopathy and diabetes; whereas cardiomyopathy and diabetes; whereas cardiomyopathy and diabetes; whereas cardiomyopathy and diabetes; whereas cardiomyopathy and diabetes; whereas cardiomyopathy and diabetes; whereas cardiomyopathy and diabetes; whereas cardiomyopathy and diabetes; whereas cardiomyopathy and diabetes; whereas cardiomyopathy and diabetes; whereas cardiomyopathy and diabetes; whereas cardiomyopathy and diabetes; whereas cardiomyopathy and diabetes; whereas cardiomyopathy and diabetes; whereas cardiomyopathy and diabetes; whereas cardiomyopathy and diabetes; whereas cardiomyopathy and diabetes; whereas cardiomyopathy and diabetes; whereas cardiomyopathy and diabetes; whereas cardiomyopathy and diabetes; whereas cardiomyopathy and diabetes; whereas cardiomyopathy and diabetes; whereas cardiomyopathy and diabetes; whereas cardiomyopathy and diabetes; whereas cardiomyopathy and diabetes; whereas cardiomyopathy and diabetes; whereas cardiomyopathy and diabetes; whereas cardiomyopathy and diabetes; whereas cardiomyopathy and diabetes; whereas cardiomyopathy and diabetes; whereas cardiomyopathy and diabetes; whereas cardiomyopathy and diabetes; whereas cardiomyopathy and diabetes; whereas cardiomyopathy and diabetes; whereas cardiomyopathy and diabetes; whereas cardiomyopathy and diabetes; whereas cardiomyopathy and diabetes; whereas cardiomyopathy and diabetes; whereas cardiomyopathy and diabetes; whereas cardiomyopathy and diabetes; whereas cardiomyopathy and diabetes; whereas cardiomyopathy and diabetes; whereas cardiomyopathy and diabetes; whereas cardiomyopathy and diabetes; whereas cardiomyopathy and diabetes; whereas cardiomyopathy and diabetes; whereas cardiomyopathy and diabetes; whereas cardiomyopathy and diabetes; whereas cardiomyopathy and diabetes; whereas cardiomyopathy and diabetes; whereas cardiomyopathy and diabetes; whereas cardiomyopathy and diabetes; whereas cardiomyopathy and diabetes; whereas cardiomyopathy and diabetes; whereas cardiomyopathy and diabetes; whereas cardiomyopathy and diabetes; whereas cardiomyopathy and diabetes; whereas cardiomyopathy and diabetes; whereas cardiomyopathy and diabetes; whereas cardiomyopathy and diabetes; whereas cardiomyopathy and diabetes; whereas cardiomyopathy and diabetes; whereas cardiomyopathy and diabetes; whereas cardiomyopathy and diabetes; whereas cardiomyopathy and diabetes; whereas cardiomyopathy and diabetes; whereas cardiomyopathy and diabetes; whereas cardiomyopathy and diabetes; whereas cardiomyopathy and diabetes; whereas cardiomyopathy and diabetes; whereas cardiomyopathy and diabetes; whereas cardiomyopathy and diabetes; whereas cardiomyopathy and diabetes; whereas cardiomyopathy and diabetes; whereas cardiomyopathy and diabetes; whereas cardiomyopathy and diabetes; whereas cardiomyopathy and diabetes; whereas cardiomyopathy and diabetes; whereas cardiomyopathy and diabetes; whereas cardiomyopathy and diabetes; whereas cardiomyopathy and diabetes; whereas cardiomyopathy and diabetes; whereas cardiomyopathy and diabetes; whereas cardiomyopathy and diabetes; whereas cardiomyopathy and diabetes; whereas cardiomyopathy and diabetes; whereas cardiomyopathy and diabetes; whereas cardiomyopathy and diabetes; whereas cardiomyopathy and diabetes; whereas cardiomyopathy and diabetes; whereas cardiomyopathy and diabetes; whereas cardiomyopathy and diabetes; whereas cardiomyopathy and diabetes; whereas cardiomyopathy and diabetes; whereas cardiomyopathy and diabetes; whereas cardiomyopathy and diabetes; whereas cardiomyopathy and diabetes; whereas cardiomyopathy and diabetes; whereas cardiomyopathy and diabetes; whereas cardiomyopathy and diabetes; whereas cardiomyopathy and diabetes; whereas cardiomyopathy and diabetes; whereas cardiomyopathy and diabetes; whereas cardiomyopathy and diabetes; whereas cardiomyopathy and diabetes; whereas cardiomyopathy and diabetes; whereas cardiomyopathy and diabetes; whereas cardiomyopathy and diabetes; whereas cardiomyopathy and diabetes; whereas cardiomyopathy and diabetes; whereas cardiomyopathy and diabetes; whereas cardiomyopathy and diabetes; whereas cardiomyopathy and diabetes; whereas cardiomyopathy and diabetes; whereas cardiomyopathy and diabetes; whereas cardiomyopathy and diabetes; whereas cardiomyopathy and diabetes; whereas cardiomyopathy and diabetes; whereas cardiomyopathy and diabetes; whereas cardiomyopathy and diabetes; whereas cardiomyopathy and diabetes; whereas cardiomyopathy and diabetes; whereas cardiomyopathy and diabetes; whereas cardiomyopathy and diabetes; whereas cardiomyopathy and diabetes; whereas cardiomyopathy and diabetes; whereas cardiomyopathy and diabetes; whereas cardiomyopathy and diabetes; whereas cardiomyopathy and diabetes; whereas cardiomyopathy and diabetes; whereas cardiomyopathy and diabetes; whereas cardiomyopathy and diabetes; whereas cardiomyopathy and diabetes; whereas cardiomyopathy and diabetes; whereas cardiomyopathy and diabetes; whereas cardiomyopathy and diabetes; whereas cardiomyopathy and diabetes; whereas cardiomyopathy and diabetes; whereas cardiomyopathy and diabetes; whereas cardiomyopathy and diabetes; whereas cardiomyopathy and diabetes; whereas cardiomyopathy and diabetes; whereas cardiomyopathy and diabetes; whereas cardiomyopathy and diabetes; whereas cardiomyopathy and diabetes; whereas cardiomyopathy and diabetes; whereas cardiomyopathy and diabetes; whereas cardiomyopathy and diabetes; whereas cardiomyopathy and diabetes; whereas cardiomyopathy and diabetes; whereas cardiomyopathy and diabetes; whereas cardiomyopathy and diabetes; whereas cardiomyopathy and diabetes; whereas cardiomyopathy and diabetes; whereas cardiomyopathy and diabetes; whereas cardiomyopathy and diabetes; whereas cardiomyopathy and diabetes; whereas cardiomyopathy and diabetes; whereas cardiomyopathy and diabetes; whereas cardiomyopathy and diabetes; whereas cardiomyopathy and diabetes; whereas cardiomyopathy and diabetes; whereas cardiomyopathy and diabetes; whereas cardiomyopathy and diabetes; whereas card...
pressure \( (p = 2 \times 10^{-13}) \) but also identified novel associations for the novel loci such as rs7500448 (pulse pressure, \( p = 4 \times 10^{-11} \)), rs1351525 (Systolic blood pressure \( p = 7 \times 10^{-7} \)) and rs33928862 (Systolic blood pressure \( p = 5 \times 10^{-4} \)). It also highlighted 21 of 71 variants without any association (\( P > 0.05 \)) with blood pressure or lipid traits (Supplementary Table 11).

**Discussion**

Using a 2-stage design, adding 10,898 new cases and 76,535 controls to the 60,801/130,681 controls/cases previously studied by the CARDIoGRAMplusC4D consortium, we identified 15 novel loci reaching genome wide significance\(^3\). The variants of these 15 loci were common, with generally low effect sizes. In keeping with previous observations, our strategy did not reveal CAD variants of low frequency (MAF \(< 1-0.05\%\)), suggesting that even other reference sets, techniques or larger sample sizes are required\(^3\). We added a relatively modest increase in cases (17.9%) compared to CARDIoGRAMplusC4D data but the number of additional controls was substantially higher (58.6%) and by filtering on a family history of ‘heart disease’ we might have decreased the number of misclassifications. These aspects of our strategy may have contributed to the relative large number of novel CAD loci compared to the latest CARDIoGRAMplusC4D that identified 10 new loci. Within UK Biobank we observed that the genetic risk score significantly predicts - and has a shared heritability with - a range of cardiovascular phenotypes, illustrating for example that genetically predicted CAD also increases risk for heart failure and atrial fibrillation, in line with observations from clinical practice.

Of the novel prioritized candidate genes, some have been previously reported for their involvement in blood vessel development. For example, \( RHOA \), part of the Ras protein family, is involved in a multitude of cellular processes via the Rho-kinase pathway which has a primary role in the regulation of contraction in vascular smooth muscle cells and promoting development of vascular remodeling\(^12\). \( CDH13 \) which encodes T-cadherin, is a regulator of vascular wall remodeling, angiogenesis and is essential for adiponectin’s vascular actions\(^13\). \( TGFB1 \), one of the most widely studied genes, is crucial in embryonic development and tissue homeostasis. The role of \( TGFB1 \) in angiogenesis is a fact and long thought to play a role in CAD development, but the exact molecular pathways are hard to tackle due to the complex and multifactorial nature\(^14\). \( rs2241718 \) near \( TGFB1 \) has been prioritized previously as a functional regulatory variant\(^15\) but is in low linkage disequilibrium \( (r^2 < 0.05) \) with the two signals identified here. Identifying two independent variants in this locus provides new opportunities to study the role of \( TGFB1 \) in CAD. The product of \( ITGB5 \), integrin \( \beta 5 \) has been studied in some detail for its role in cell adhesion and integrin-mediated signaling. It is believed that \( ITGB5 \) is able to exert pro-angiogenic effects by enhancing

![Figure 2. Gene-networks of the meta gene-sets that DEPICT prioritized at FDR < 0.05. Sizes of the nodes reflect the eigenvector centrality, an indicator of a node’s centrality in the network.](image-url)
This process has an unfavorable role in atherosclerosis: the formation of ICAM-1-induced endothelial docking structures that facilitate transendothelial migration and new candidate target for therapy.

Whether this variant is causally implicated in CAD through mechanisms of

**SGEF**

and lipids. Future studies are necessary to determine the exact molecular mechanisms underlying rs433903 and associated with CAD in humans and is not convincingly associated with other phenotypes such as blood pressure

**Table 3.** Associations in UK Biobank (N = 143,936) between the genetic risk score based on the 71 genome wide significant CAD variants and cardiovascular profile. Effect estimates with 95% Confidence Interval (CI) are shown as odds ratios for categorical variables (current smoking, cardiovascular disease, atherosclerosis, hypercholesterolemia, hypertension, diabetes, myocardial infarction, heart failure, atrial fibrillation/flutter, cerebral Infarction and TIA, device implantation, beta-blockers and calcium-channel blockers) and β estimates for quantitative variables (body-mass index, resting heart rate, systolic and diastolic blood pressure, pulse pressure, mean arterial pressure and arterial stiffness index). Abbreviation: N = Number, CI = Confidence Interval, TIA = Transient Ischemic Attack.

| Phenotype                          | N deaths (%) | Hazard Ratio (95% CI) | P value |
|------------------------------------|--------------|-----------------------|---------|
| Coronary Artery Disease            | 723 (0.5%)   | 1.75 (1.48 to 2.08)   | 4.90 × 10⁻¹¹ |
| Myocardial Infarction              | 210 (0.1%)   | 1.93 (1.41 to 2.63)   | 3.40 × 10⁻¹² |
| Heart failure                      | 219 (0.2%)   | 1.39 (1.02 to 1.88)   | 3.69 × 10⁻¹² |
| Cardiomyopathy                     | 40 (0.0%)    | 1.18 (0.58 to 2.40)   | 6.48 × 10⁻¹⁰ |
| Cerebral Infarction and TIA        | 124 (0.1%)   | 1.32 (0.87 to 1.98)   | 1.89 × 10⁻⁹  |
| All cause mortality                | 4373 (3.0%)  | 1.02 (0.95 to 1.09)   | 5.65 × 10⁻⁴  |
| Cardiovascular mortality (as primary cause of death) | 892 (0.6%) | 1.46 (1.26 to 1.70) | 9.08 × 10⁻⁹ |

**Table 2.** Cox survival model predicting hazard of death using the genetic risk score based on the 71 genome wide significant CAD variants. Abbreviations: N = Number, CI = Confidence Interval, TIA = Transient Ischemic Attack.

| Phenotype                          | N individuals (%) | Beta (linear Regression) or odds ratio (logistic regression) (95% CI) | P value |
|------------------------------------|-------------------|---------------------------------------------------------------------|---------|
| Body-mass index                    | 143,442 (99.7%)   | −0.08 (−0.14 to −0.02)                                              | 5.80 × 10⁻³ |
| Height                             | 143,595 (99.8%)   | −0.16 (−0.24 to −0.09)                                              | 2.78 × 10⁻⁵ |
| Resting heart rate                 | 135,846 (94.4%)   | −0.45 (−0.59 to −0.31)                                              | 2.03 × 10⁻¹⁸ |
| Blood pressure                     |                   |                                                                     |         |
| Systolic                           | 143,770 (99.9%)   | 0.61 (0.40 to 0.82)                                                 | 1.27 × 10⁻⁴ |
| Diastolic                          | 143,770 (99.9%)   | −0.02 (−0.14 to 0.10)                                               | 7.60 × 10⁻¹¹ |
| Pulse pressure                     | 143,770 (99.9%)   | 0.63 (0.48 to 0.78)                                                 | 1.65 × 10⁻¹⁴ |
| Mean arterial pressure             | 143,770 (99.9%)   | 0.19 (0.05 to 0.33)                                                 | 7.14 × 10⁻³ |
| Arterial stiffness index           | 54,184 (37.6%)    | −0.02 (−0.08 to 0.04)                                               | 5.38 × 10⁻⁹ |
| Smoking current                    | 18,282 (14.5%)    | −0.05 (0.91 to 0.98)                                                | 5.45 × 10⁻³ |
| Medical Conditions                 |                   |                                                                     |         |
| Coronary Artery Disease            | 10,898 (8.2%)     | 2.21 (2.11 to 2.32)                                                 | 1.76 × 10⁻⁲⁷ |
| Hypertension                       | 48,927 (37.3%)    | 1.18 (1.15 to 1.22)                                                 | 5.89 × 10⁻³ |
| Diabetes                           | 10,486 (7.9%)     | 1.10 (1.05 to 1.16)                                                 | 5.91 × 10⁻⁴ |
| Myocardial Infarction              | 5,145 (3.7%)      | 2.35 (2.20 to 2.51)                                                 | 2.05 × 10⁻¹³ |
| Heart failure                      | 2,143 (1.5%)      | 1.43 (1.29 to 1.58)                                                 | 2.76 × 10⁻¹² |
| Cardiomyopathy                     | 522 (0.4%)        | 1.02 (0.84 to 1.25)                                                 | 8.39 × 10⁻⁹ |
| Atrial fibrillation/flutter         | 5,279 (3.8%)      | 1.10 (1.03 to 1.18)                                                 | 2.90 × 10⁻³ |
| Cerebral Infarction and TIA        | 4,043 (2.9%)      | 1.16 (1.08 to 1.25)                                                 | 4.68 × 10⁻⁵ |
| Device implantation                | 1,606 (1.1%)      | 1.51 (1.35 to 1.69)                                                 | 1.76 × 10⁻¹² |
| Medication                          |                   |                                                                     |         |
| Beta-blockers                      | 10,576 (7.9%)     | 1.42 (1.36 to 1.49)                                                 | 1.15 × 10⁻⁴⁸ |
| Calcium channel-blockers           | 10,993 (8.3%)     | 1.17 (1.12 to 1.23)                                                 | 3.19 × 10⁻¹⁵ |

The binding capacity of circulating angiogenic cells to endothelial cells

Our pathway analyses also suggest that factors related to angiogenesis (‘blood vessel development’ and ‘regulation of cell motility’) are indeed central among the CAD loci, supplementing previously performed pathway analyses.

We also identified a novel CAD locus (rs433903) harboring **SGEF**. **SGEF** has been described to contribute to the formation of ICAM-1-induced endothelial docking structures that facilitate transendothelial migration and adhesion of leukocytes. This process has an unfavorable role in atherosclerosis: **SGEF** mice demonstrate a significant reduction in the formation of atherosclerotic plaque and was suggested as a novel therapeutic target, also since there appeared to be no other negative phenotypes. Here, we demonstrate that rs433903 near **SGEF** is associated with CAD in humans and is not convincingly associated with other phenotypes such as blood pressure and lipids. Future studies are necessary to determine the exact molecular mechanisms underlying rs433903 and whether this variant is causally implicated in CAD through mechanisms of **SGEF** to further establish **SGEF** as a new candidate target for therapy.
For dichotomous traits, the heritability on the observed 0-1 scale was transformed to heritability based on genome wide variation, $h^2_g = \text{heritability based on genome wide variation, Se = Standard error, TIA = Transient Ischemic Attack (h2g); standard error (SE); N.A. ; not applicable.}$

The majority of preventive CAD medication is currently directed towards lowering LDL cholesterol and blood pressure, both of which are also closely associated with CAD on a genetic level, and considered to be causally related\textsuperscript{20-22}. Genetic variants lacking any association with blood pressure or lipids might be of increased interest to be considered as novel (first in class) therapeutic targets that act independently from blood pressure or lipid lowering medication. However, our analyses are limited by the associative nature. To establish further evidence of the true causal genes and mechanisms underlying each association, further functional experiments are essential. We are the first to have observed a significant genetic correlation between CAD and heart failure. The degree of shared heritability between CAD and heart failure was estimated to be as high as 0.68. We also observed that genetic risk for CAD was strongly associated with the occurrence of heart failure due to CAD, and predicts death of heart failure with similar effects. It is well known that CAD plays a major role in heart failure, prevention of CAD is essential to maintaining functional myocyte reserve and preventing left ventricular systolic dysfunction\textsuperscript{23}. Furthermore, a significant correlation and shared heritability was observed between the genetic risk score of CAD and increased risk of atrial fibrillation, perhaps due to atrial infarction but shared mechanisms of inflammation may also be responsible\textsuperscript{24}. We could not only explain death due to CAD using our genetic risk score, in line with other studies\textsuperscript{25}, but could even predict progression of CAD as indicated by the significant association with recurrent CAD. A genetic risk score may be helpful to discriminate individuals at high risk of CAD and to direct more intensive preventive therapies. Future studies should be focused at replicating the newly identified loci and at further elucidating the molecular and pathophysiological mechanisms underlying CAD.

**Table 4.** Heritability estimates for cardiovascular traits and the shared heritability between each trait and CAD in all UK Biobank Participants based on common genetic variation under the additive model ($h^2_g$). For dichotomous traits, the heritability on the observed 0-1 scale was transformed to $h^2_g$ on the unobserved continuous liability scale by a linear transformation. Abbreviations: $h^2_g =$ heritability based on genome wide variation, Se = Standard error, TIA = Transient Ischemic Attack (h2g); standard error (SE); N.A. ; not applicable.

**Materials and Methods**

**UK biobank individuals.** UK Biobank recruited participants with an age range of 40–69 years that registered with a general practitioner of the UK National Health Service (NHS). Between 2006–2010, in total 503,325 individuals were included. All study participants provided informed consent and the study was approved by the North West Multi-centre Research Ethics Committee. Detailed methods used by UK Biobank have been described elsewhere.
Ascertainment of resting coronary artery disease and controls. The prevalence and incidence of coronary artery disease conditions and events were captured by data collected at the Assessment Centre in-patient Health Episode Statistics (HES), CAD was defined using the following ICD 10 codes: I21-I25 covering ischaemic heart disease and the following Office of Population Censuses and Surveys Classification of Interventions and Procedures, version 4 (OPCS-4) codes: K40-K46, K49, K50 and K75 which includes replacement, transluminal balloon angioplasty, and other therapeutic transluminal operations on coronary artery and percutaneous transluminal balloon angioplasty and insertion of stent into coronary artery. The exact phenotype definitions of UK Biobank are described in the supplementary note under section “Definitions used for UK Biobank analyses”. Individuals from the control group were excluded if their mother, father or sibling were reported to suffer from ‘heart disease’ to increase the true CAD/non-CAD ratio for our analysis.

Genotyping and Imputation. Of the 500 thousand individuals with phenotype data in UK Biobank, 152,249 (25%) are currently genotyped. Genotyping, quality control and imputation was performed by UK Biobank and described in detail elsewhere30-36. Briefly, genotyping of 102,326 individuals was performed using the UK Biobank Axiom array (Affymetrix), and an additional 49,923 individuals were genotyped as part of the UK Biobank Lung Exome Variant Evaluation (UK BiLEVE) project. The Welcome Trust Centre for Human Genetics performed quality control before imputation and imputed the dataset using a merged reference panel of 1000 Genomes, phase 3 and UK10K. The imputed dataset consisted of 72,355,667 genetic variants. For this work, genetic variants were included only if the imputation quality was greater than 0.3 and MAF > 0.005 in line with the CARDIoGRAMplusC4D analysis, leaving 12,248,858 genetic variants. Participants were excluded based on gender mismatch, high missingness and high heterozygosity (n = 662). We also removed 8,874 individuals based on relatedness (3rd degree or closer9), one of each related pair was excluded based on the highest missingness.

Statistical Analysis. We selected genetic variants for replication from the CARDIoGRAMplusC4D GWAS (downloaded from: http://www.cardiogramplusc4d.org/downloads) by filtering on p < 1 x 10^-5 and linkage disequilibrium using the PLINK clumping procedure (‘–clump-kb 5000 –clump-r2 0.05’, 1000 Genomes phase 1), after which we determined the number of 2-Megabase-loci, by assigning 1 Megabase regions at either side of the highest associated variant per locus (designated the sentinel genetic variant). Logistic regression analyses between genetic variants and the 10,898 CAD cases and 76,535 controls in UK Biobank were performed after adjustments for age, sex, the first 15 Principal Components to control for population stratification, and the genotyping array used. To account for multiple testing and declare novel loci we applied a replication p of FDR < 0.05 in UK Biobank and a genome wide significance threshold of p < 5 x 10^-8 in the inverse-variance meta-analysis between the summary statistics of UK Biobank and CARDIoGRAMplusC4D.

Pathway analyses. The DEPICT Framework was used to identify enriched pathways, prioritize candidate genes at each loci and selects relevant tissues/cell types from co-expression networks of genes underlying the associated loci7 (see Pers et al. for a detailed description). We applied DEPICT on CARDIoGRAMplusC4D results at p < 1 x 10^-5 which identified 194 independent loci using default settings (PLINK parameters, ‘–clump-p1 1e-5 –clump-kb 500 –clump-r2 0.01’), containing 489 genes. The gene prioritization, gene set enrichment and tissue/cell type enrichment analyses were run using the default settings in DEPICT (1000 G dataset). We applied the affinity propagation method27 to identify correlated genesets and for each correlated group the exemplar-geneset, which was named ‘meta-geneset’, and used Gephi (www.gephi.org)28 to visualize the pearson correlation between pathways and calculate the centrality measures of each node (Fig. 2).

Genetic risk score analyses & (shared) heritability of CAD. To study the relationship of CAD with other cardiovascular phenotypes, we created a weighted genetic risk score by summing the number of CAD risk-increasing alleles weighted (multiplied) by its β (estimated using the 1000 genomes meta-analysis30) of each associated genetic variant assuming an additive effect. We performed a linear or logistic regression adjusted for age, gender, principle components and genotyping chip between the genetic risk score and cardiovascular phenotype. Cox regression analysis adjusted for age, gender, principle components and the genotyping chip was used to evaluate the predictive power of the genetic risk score on mortality and recurrent CAD events. Bivariate REML analyses were performed using BOLT-REML31 to estimate the heritability of CAD and the genetic correlation of CAD with other cardiovascular traits. All directly genotyped variants that passed quality control were extracted from the imputed dataset (to ensure 100% call rate) and pruned on linkage disequilibrium (r^2 < 0.05) to obtain roughly 500 k variants, as recommended31. Liability scale was estimated for dichotomous traits using linear transformation32. Gender, age, principle components and genotyping chip we included as covariates in all analyses.

Identification of candidate genes. We prioritized candidate genes for each of the 71-genome wide significant variants that were shared in 52 loci, based on the following criteria:

1. The nearest gene or any gene located within 10 kb of the sentinel genetic variant.
2. Any gene containing protein coding variants in linkage disequilibrium (r^2 > 0.8, UK Biobank) with the sentinel genetic variant (Supplementary Table 4).
3. Expression QTL (eQTL) analyses in cis; we search for eQTLs (sentinel genetic variants or genetic variants in linkage disequilibrium, r^2 > 0.8, UK Biobank) in an eQTL dataset that was compiled from multiple tissues, including those of GTEx v630, STARnet31 and large eQTL datasets of blood32-34 (see Supplementary Table 5). We only considered eQTLs for which the top-eQTL was in linkage disequilibrium (r^2 > 0.8, UK Biobank) with the sentinel genetic variant and for which the eQTL p < 1 x 10^-6.
4. DEPICT-genes (see section “pathway analyses” for more details and Supplementary Tables 6-8).


References
1. Task Force, M. et al. ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. Eur. Heart J. 34, 2949–3003 (2013).
2. Kullo, I. J. et al. Incorporating a Genetic Risk Score into Coronary Heart Disease Risk Estimates: Effect on LDL Cholesterol Levels (the MIGENES Clinical Trial). Circulation doi:10.1161/CIRCULATIONAHA.115.020109 (2016).
3. Nikpay, M. et al. A comprehensive 1,000 Genomes-based genome-wide association meta-analysis of coronary artery disease. Nat. Genet. 47, 1121–1130 (2015).
4. Plenge, R. M., Scollnick, E. M. & Altshuler, D. Validating therapeutic targets through human genetics. Nat. Rev. Drug Discov. 12, 581–594 (2013).
5. Interleukin-6 Receptor Mendelian Randomisation Analysis (IL6R MR) Consortium. The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysis. Lancet Lond. Engl. 379, 1214–1224 (2012).
6. Genotyping and quality control of UK Biobank, a large-scale, extensively phenotyped prospective resource. (2015).
7. Pers, T. T. H. et al. Biological interpretation of genome-wide association studies using predicted gene functions. Nat. Commun. 6, 5890 (2015).
8. Loh, P. R. et al. Efficient Bayesian mixed-model analysis increases association power in large cohorts. Nat. Genet. 47, 284–290 (2015).
9. Global Lipids Genetics Consortium. Discovery and refinement of loci associated with lipid levels. Nat. Genet. 45, 1274–1283 (2013).
10. Locke, A. E. et al. Genetic studies of body mass index yield new insights for obesity biology. Nature 518, 197–206 (2015).
11. Shungin, D. et al. New genetic loci link adipose and insulin biology to body fat distribution. Nature 518, 187–196 (2015).
12. Shimokawa, H., Sumamura, S. & Satoh, K. RhoA/Rho-Kinase in the Cardiovascular System. Circ. Res. 118, 352–366 (2016).
13. Parker-Duffen, J. et al. T-cadherin Is Essential for Adiponectin-mediated Revascularization. J. Biol. Chem. 288, 24886–24897 (2013).
14. Zeng, L., Dang, T. A. & Schunkert, H. Genetics links between transforming growth factor β pathway and coronary disease. Atherosclerosis 253, 237–246 (2016).
15. Miller, C. L. et al. Integrative functional genomics identifies regulatory mechanisms at coronary artery disease loci. Nat. Commun. 7, 12092 (2016).
16. Leithert-Neitler, M. et al. Overexpression of Integrin δ5 Enhances the Paracrine Properties of Circulating Angiogenic Cells via Src Kinase–Mediated Activation of STAT3. Arterioscler. Thromb. Vasc. Biol. 30, 1398–1406 (2010).
17. Ghosh, S. et al. Systems Genetics Analysis of GWAS reveals Novel Associations between Key Biological Processes and Coronary Artery Disease. Arterioscler. Thromb. Vasc. Biol. 35, 1712–1722 (2015).
18. Samson, T. et al. The Gauanine-Nucleotide Exchange Factor SGEF Plays a Crucial Role in the Formation of Atherosclerosis. PLos ONE 8, (2013).
19. Bitoun, P. Sgf controls macular, corollus callossus and hippocampal function and development, liver homeostasis, functions of the immune system, fever response atherosclerosis and tumorigenic cell growth. (2012).
20. Studies, T. I. C. for B. P. G.-W. A. Genetic variants in novel pathways influence blood pressure and cardiovascular disease risk. Nature 478, 103–109 (2011).
21. Do, R. et al. Common variants associated with plasma triglycerides and risk for coronary artery disease. Nat. Genet. 45, 1345–1352 (2013).
22. Lieb, W. et al. Genetic predisposition to higher blood pressure increases coronary artery disease risk. Hypertension 61, (2013).
23. Doshi, D. et al. Underutilization of Coronary Artery Disease Testing Among Patients Hospitalized With New-Onset Heart Failure. J. Am. Coll. Cardiol. 66, 450–458 (2016).
24. Fu, Y.-F., Chen, Y.-J., Lin, Y.-J. & Chen, S.-A. Inflammation and the pathogenesis of atrial fibrillation. Nat. Rev. Cardiol. 12, 230–243 (2015).
25. Khera, A. V. et al. Genetic Risk, Adherence to a Healthy Lifestyle, and Coronary Disease. N. Engl. J. Med. 366, null (2016).
26. Eppinga, R. N. et al. Identification of genomic loci associated with resting heart rate and shared genetic predictors with all-cause mortality. Nat. Genet. 48, 1557–1563 (2016).
27. Bodenhofer, U., Kohlmeyer, A. & Hochreiter, S. APCluster: an R package for affinity propagation clustering. Bioinformatics 27, 2463–2464 (2011).
28. Bastian, M., Heymann, S. & Jacomy, M. Gephi: An Open Source Software for Exploring and Manipulating Networks. (2009).
29. Lee, S. H., Wray, N. R., Goddard, M. E. & Visscher, P. M. Estimating missing heritability for disease from genome-wide association studies. Am. J. Hum. Genet. 88, 294–305 (2011).
30. Lonsdale, J. et al. The Genotype–Tissue Expression (GTEx) project. Nat. Genet. 45, 580–585 (2013).
31. Franzeén, O. et al. Cardiometabolic risk loci share downstream cis- and trans-gene regulation across tissues and diseases. Science 353, 827–830 (2016).
32. Westra, H.-J. et al. Systematic identification of trans eQTLs as putative drivers of known disease associations. Nat. Genet. 45, 1238–1243 (2013).
33. Bonder, M. J. et al. Disease variants alter transcription factor levels and methylation of their binding sites. bioRxiv doi:10.1101/033084 (2015).
34. Zhernakova, D. et al. Hypothesis-free identification of modulators of genetic risk factors. bioRxiv doi:10.1101/033217 (2015).

Acknowledgements
R.N.E. is supported by the Netherlands organization for health research and development (ZonMw grant 90.700.441). N.V. is supported by ICIN-NHI and Marie Sklodowska-Curie GF (call: H2020-MSCA-IF-2014, Project ID: 661395)

Author Contributions
N.V. and P.H. study design; N.V., R.N.E. and Y.H. conducted the experiment, analysed and interpreted the results; N.V., R.N.E., Y.H. and P.H. manuscript writing. All authors reviewed the manuscript.

Additional Information
Supplementary information accompanies this paper at doi:10.1038/s41598-017-03062-8

Competing Interests: The authors declare that they have no competing interests.

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
